Novartis


Novartis   link
Ort: Basel
Hauptporte - MainGate, Fabrikstrasse 2, 4056 Basel

Kategorie: Pharmakologie
Verbunden:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

logo

Pharmakologie - Gesundheit - 16.04
Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients with relapsing forms of multiple sclerosis (RMS) according to new post hoc data from the Phase III ASCLEPIOS trials, further supporting Kesimpta as a
Pharmakologie - Gesundheit - 15.04

Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra Follows recent initial agreements for providing manufacturing capacity for CureVac and BioNtech     Basel, April 15, 2021 - Novartis has signed an i

Pharmakologie - Gesundheit - 30.03

There are more than 1 million people living with multiple sclerosis (MS) in Europe 1 , Kesimpta (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable safety profile with the flexibility of self-administration at home via the Sensoready autoinjector pen 2,3

Pharmakologie - 23.03

Basel, March 23, 2021 - On Saturday, March 6, 2021, SonntagsBlick published an interview with Novartis Chairman Joerg Reinhardt, Ph.D., in connection with the 25th anniversary of the founding of the company.

Pharmakologie - Gesundheit - 15.03

Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse events Real-world data indicate older children (aged =6 months) achieved clinically meaningful benefit with Zolgensma alone,

Pharmakologie - 5.03

Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021 Thomas Kendris appointed Chief Legal Officer ad interim Basel, March 5, 2021 - Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company.

Gesundheit - Pharmakologie - 30.03

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74 Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors 1 ,2 ,3 Novartis Oncology continues to reimagine cancer care thro

Pharmakologie - Gesundheit - 23.03

Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1 VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in

Verwaltung - Recht - 22.03

Basel, March 22, 2021 - Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021.

Pharmakologie - Gesundheit - 9.03

Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments 1 Canakinumab development program continues; two Phase III non-small cell lung cancer clinical trials are ongoing in first-line and adjuvant se

Gesundheit - 4.03

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting.






Website Preview